Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions
-
Published:2024-02-15
Issue:2
Volume:11
Page:185
-
ISSN:2306-5354
-
Container-title:Bioengineering
-
language:en
-
Short-container-title:Bioengineering
Author:
Kim Doo Nam1ORCID, McNaughton Andrew D.1ORCID, Kumar Neeraj1ORCID
Affiliation:
1. Pacific Northwest National Laboratory, 902 Battelle Blvd., Richland, WA 99352, USA
Abstract
This perspective sheds light on the transformative impact of recent computational advancements in the field of protein therapeutics, with a particular focus on the design and development of antibodies. Cutting-edge computational methods have revolutionized our understanding of protein–protein interactions (PPIs), enhancing the efficacy of protein therapeutics in preclinical and clinical settings. Central to these advancements is the application of machine learning and deep learning, which offers unprecedented insights into the intricate mechanisms of PPIs and facilitates precise control over protein functions. Despite these advancements, the complex structural nuances of antibodies pose ongoing challenges in their design and optimization. Our review provides a comprehensive exploration of the latest deep learning approaches, including language models and diffusion techniques, and their role in surmounting these challenges. We also present a critical analysis of these methods, offering insights to drive further progress in this rapidly evolving field. The paper includes practical recommendations for the application of these computational techniques, supplemented with independent benchmark studies. These studies focus on key performance metrics such as accuracy and the ease of program execution, providing a valuable resource for researchers engaged in antibody design and development. Through this detailed perspective, we aim to contribute to the advancement of antibody design, equipping researchers with the tools and knowledge to navigate the complexities of this field.
Funder
Laboratory Directed Research and Development Program at the Pacific Northwest National Laboratory
Reference192 articles.
1. Predicting Antibody Developability Profiles through Early Stage Discovery Screening;Bailly;mAbs,2020 2. Wilman, W., Wróbel, S., Bielska, W., Deszynski, P., Dudzic, P., Jaszczyszyn, I., Kaniewski, J., Młokosiewicz, J., Rouyan, A., and Satława, T. (2022). Machine-designed biotherapeutics: Opportunities, feasibility and advantages of deep learning in computational antibody discovery. Brief. Bioinform., 23. 3. Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsia, H.-Z., Li, H.-J., and Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci., 27. 4. Deep Learning in Therapeutic Antibody Development;Shaver;Methods Mol. Biol.,2022 5. Graves, J., Byerly, J., Priego, E., Makkapati, N., Parish, S.V., Medellin, B., and Berrondo, M. (2020). A Review of Deep Learning Methods for Antibodies. Antibodies, 9.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|